Safety is priority over efficacy in COVID vaccine for children -- FDA | Inquirer

Safety is priority over efficacy in COVID vaccine for children — FDA

By: - Reporter /
/ 01:34 PM December 13, 2021

MANILA, Philippines —Experts are prioritizing the safety of children over COVID-19 vaccines’ efficacy before it could be approved for use, Food and Drug Administration Director General Eric Domingo said on Monday.

“Ang primary concern po natin, lalo na the children get younger and smaller, is ‘yung safety. Before the efficacy, ‘yun po munang safety ang tinitignan ng atin pong mga eksperto diyan bago natin payagan,” Domingo said during the Laging Handa briefing, referring to Pfizer’s application for emergency use authorization (EUA) of its COVID-19 vaccine for children aged five to 11.

(Our primary concern, especially with the children getting younger and smaller, is safety. Before the efficacy, our experts are looking into safety first.)

Article continues after this advertisement

“So far, ‘yung clinical trial data, wala naman pong nakikita na very unusual or tinatawag nating signals of very severe na mga adverse events kundi karamihan ng nakita rin sa mga trials ay mga mild katulad din po ng mga naramdaman sa ibang mga bakuna na ibinibigay sa mga bata,” he added.

FEATURED STORIES

(So far, clinical trial data shows that we do not have very unusual or what we call signals of very severe adverse events. Most of those observed during trials are mild,  similar to those observed in other vaccines for children.)

Should the Pfizer vaccine be approved for children below 12 years old, Domingo assured that the government will continue to monitor the minors who received a vaccine.

Article continues after this advertisement

“Ito po, titingnan natin during the evaluation and of course, ‘pag sakali naman na i-roll out natin, continuous din po talaga ang monitoring. Dahil under EUA, talagang kasama po nu’n, maigting na pagbabantay to make sure lamang na kung mayroong mga unusual tayo na nakikita ay nahuhuli po natin agad,” he assured.

Article continues after this advertisement

(We will see during the evaluation and of course, should we roll out the vaccines, we will continuously monitor them. Because under their EUA, strict monitoring is included to make sure that if there is something unusual, the same could be promptly addressed.)

Citing data, Domingo said that Pfizer vaccine has a 90.7 percent efficacy rate for children in the five to 11 age bracket.

Currently, Pfizer’s COVID-19 vaccine could be administered to minors aged 12 and above.

 gsg
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

For more news about the novel coronavirus click
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this

MOST READ
www
www
globalnation
business
opinion
TAGS: COVID-19, Eric Domingo, FDA, Pfizer

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.